Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma-Reference-Cited by-同舟云学术

Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma

Published:2024-09 Issue: Volume:195 Page:107928
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Mansfield Aaron S.,Vivien Yin Jun,Bradbury Penelope,Kwiatkowski David J.,Patel Shiven,Bazhenova Lyudmila A.,Forde Patrick,Lou Yanyan,Dizona Paul,Villaruz Liza C.,Arnold Susanne M.,Khalil Maya,Kindler Hedy L.,Koczywas Marianna,Pacheco Jose,Rolfo Christian,Xia Bing,Mikula Elizabeth,Chen Li,Patel Kashish,Smith Katherine E.R.,Cao Liang,Shapiro Geoffrey,Costello Brian A.,Adjei Alex,Sharon Elad,Moscow Jeffrey A.,Zamboni William,Hassan Raffit

Publisher

Elsevier BV

Reference37 articles.

1. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial;Alley;Lancet Oncol.,2017

2. Clinical Efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT);Okada;Clin. Cancer Res.,2019

3. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021

4. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial;Forde;Nat. Med.,2021

5. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in;Nowak;Lancet Oncol.,2020